July was yet another bumper month for pharma, which saw France-based Sanofi ink a $2bn deal with Skyhawk Therapeutics to develop small molecule drugs for oncology and immunology. (Also see "Sanofi Continues Hunt For External Innovation With Skyhawk Deal" - Scrip, 6 July, 2022.)
In the medtech space, AbbVie gave iStar Medical an upfront cash payment to continue the development of its glaucoma devices, with the deal also granting AbbVie the option...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?